ES2155995T3 - Compuestos de 4-fenilpiperidina. - Google Patents

Compuestos de 4-fenilpiperidina.

Info

Publication number
ES2155995T3
ES2155995T3 ES97926276T ES97926276T ES2155995T3 ES 2155995 T3 ES2155995 T3 ES 2155995T3 ES 97926276 T ES97926276 T ES 97926276T ES 97926276 T ES97926276 T ES 97926276T ES 2155995 T3 ES2155995 T3 ES 2155995T3
Authority
ES
Spain
Prior art keywords
group
sub
alkyl
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97926276T
Other languages
English (en)
Spanish (es)
Inventor
Franciscus Bernardus Benneker
Dalen Frans Van
Jacobus Maria Lemmens
Theodorus Hendricus Ant Peters
Frantisek Picha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26647319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon BV filed Critical Synthon BV
Application granted granted Critical
Publication of ES2155995T3 publication Critical patent/ES2155995T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES97926276T 1997-06-10 1997-06-10 Compuestos de 4-fenilpiperidina. Expired - Lifetime ES2155995T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/872,023 US5874447A (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds for treating depression
PCT/NL1997/000328 WO1998056787A1 (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds

Publications (1)

Publication Number Publication Date
ES2155995T3 true ES2155995T3 (es) 2001-06-01

Family

ID=26647319

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97926276T Expired - Lifetime ES2155995T3 (es) 1997-06-10 1997-06-10 Compuestos de 4-fenilpiperidina.

Country Status (25)

Country Link
US (4) US5874447A (OSRAM)
EP (2) EP1078925A1 (OSRAM)
JP (1) JP2002503248A (OSRAM)
KR (1) KR100543614B1 (OSRAM)
AT (1) ATE200781T1 (OSRAM)
AU (1) AU3108097A (OSRAM)
BG (1) BG64315B1 (OSRAM)
BR (1) BR9714787A (OSRAM)
CA (1) CA2293247C (OSRAM)
CZ (1) CZ295301B6 (OSRAM)
DE (2) DE29724281U1 (OSRAM)
DK (1) DK0994872T3 (OSRAM)
EE (2) EE03970B1 (OSRAM)
ES (1) ES2155995T3 (OSRAM)
GR (1) GR3035784T3 (OSRAM)
HU (1) HUP0003141A3 (OSRAM)
IL (1) IL133366A (OSRAM)
IS (2) IS1927B (OSRAM)
NO (3) NO317371B1 (OSRAM)
PL (1) PL188450B1 (OSRAM)
PT (1) PT994872E (OSRAM)
SI (1) SI0994872T1 (OSRAM)
SK (1) SK283394B6 (OSRAM)
TR (2) TR200201156T2 (OSRAM)
WO (1) WO1998056787A1 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
KR20010042552A (ko) * 1998-04-09 2001-05-25 피터 기딩스 파록세틴 말레에이트
AU724845B3 (en) * 1998-07-02 2000-09-28 Smithkline Beecham Plc Novel compound
US20010023252A1 (en) * 1998-07-02 2001-09-20 Smithkline Beecham Plc Novel compound
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
WO2000008016A1 (en) * 1998-08-08 2000-02-17 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9828780D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828779D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828781D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
DK1109806T3 (da) * 1999-07-01 2003-12-22 Italfarmaco Spa Komplekser af paroxetin med cyclodextriner eller cyclodextrinderivater
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1280775A1 (en) * 2000-05-12 2003-02-05 Synthon B.V. TOSYLATE SALTS OF 4-(p-FLUOROPHENYL)-PIPERIDINE-3-CARBINOLS
DE60007782T2 (de) * 2000-05-12 2004-12-09 Synthon B.V. Piperidinverbindungen und verfahren zu deren herstellung
IL154422A0 (en) * 2000-08-28 2003-09-17 Synthon Bv Paroxetine compositions and processes for making the same
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20030032809A1 (en) * 2001-04-25 2003-02-13 Subhash P. Upadhyaya Optimized procedures for the manufacture of paroxetine salts
CA2457382A1 (en) * 2001-06-13 2002-12-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
WO2003020717A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AR039163A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CA2616383C (en) * 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CN101855218A (zh) * 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
US20120077842A1 (en) 2009-08-19 2012-03-29 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013216123B2 (en) * 2012-01-31 2016-10-20 Eisai R&D Management Co., Ltd. Paroxetine derivative
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN110831597A (zh) 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT99678B (de) * 1921-09-21 1925-04-10 Hoechst Ag Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen.
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5258388A (en) 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
JPH08220486A (ja) * 1994-12-14 1996-08-30 Kato Kogei:Kk 眼鏡フレーム
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
HUP9900318A3 (en) * 1995-05-17 2001-09-28 Novo Nordisk As Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2234640A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384711A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Optical resolution of a piperidine derivative
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
PT994872E (pt) 2001-09-28
SK161999A3 (en) 2000-08-14
US7598271B1 (en) 2009-10-06
EE03970B1 (et) 2003-02-17
CZ295301B6 (cs) 2005-07-13
GR3035784T3 (en) 2001-07-31
US5874447A (en) 1999-02-23
PL188450B1 (pl) 2005-02-28
DK0994872T3 (da) 2001-05-28
IS7098A (is) 2004-01-08
EE9900570A (et) 2000-08-15
TR199903025T2 (xx) 2000-07-21
DE69704679T2 (de) 2001-09-13
BG64315B1 (bg) 2004-09-30
HUP0003141A3 (en) 2001-04-28
IS1927B (is) 2004-04-15
HUP0003141A2 (en) 2001-03-28
CZ429599A3 (cs) 2000-04-12
KR20010013615A (ko) 2001-02-26
NO20033765L (no) 2000-02-09
EE200200633A (et) 2003-02-17
US20090326233A1 (en) 2009-12-31
SI0994872T1 (OSRAM) 2001-08-31
WO1998056787A1 (en) 1998-12-17
PL336895A1 (en) 2000-07-17
IS5249A (is) 1999-11-16
DE29724281U1 (de) 2000-08-10
NO20033765D0 (no) 2003-08-25
NO317371B1 (no) 2004-10-18
IL133366A (en) 2005-11-20
CA2293247C (en) 2005-04-12
KR100543614B1 (ko) 2006-01-20
NO995455D0 (no) 1999-11-08
NO20033766D0 (no) 2003-08-25
TR200201156T2 (tr) 2002-07-22
DE69704679D1 (de) 2001-05-31
CA2293247A1 (en) 1998-12-17
EP0994872B1 (en) 2001-04-25
HK1027352A1 (en) 2001-01-12
EP0994872B9 (en) 2001-12-05
NO20033766L (no) 2000-02-09
EP0994872A1 (en) 2000-04-26
BG103980A (en) 2000-07-31
BR9714787A (pt) 2000-07-18
AU3108097A (en) 1998-12-30
ATE200781T1 (de) 2001-05-15
IL133366A0 (en) 2001-04-30
SK283394B6 (sk) 2003-07-01
US6900327B2 (en) 2005-05-31
JP2002503248A (ja) 2002-01-29
EP1078925A1 (en) 2001-02-28
US20010031767A1 (en) 2001-10-18
NO995455L (no) 2000-02-09

Similar Documents

Publication Publication Date Title
ES2155995T3 (es) Compuestos de 4-fenilpiperidina.
MX9505063A (es) Tetralina- e indano-1h-imidazoles.
CO4950531A1 (es) Analogos de la vitamina d3 composciiones farmaceuticas que los contienen
ZA876345B (en) Phenolic corrosion inhibitors for coating materials
AR002041A1 (es) Nuevos taxoides, procedimiento para prepararlos, los compuestos intermediarios de aplicacion con dicho procedimiento, procedimiento parapreparar dichos intermediarios y las composiciones farmaceuticas que contienen dichos taxoides.
ES2125161B1 (es) Nuevos derivados de 2-(3h)-oxazolona.
DK424585A (da) Aryleddikesyrederivater
ES2070238T3 (es) Emulsion de lipidos que contiene un analogo de prostaglandina.
ATE248814T1 (de) 16-ene-vitamin d derivate
FI890520A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2- (piperidin-4-ylmetyl) -1,2,3,4 -tetrahydroisokinolinderivat.
ES2081858T3 (es) Compuestos de beta-fenoxinitrilo.
ES2159921T3 (es) Imidazolinas sustituidas por un nucleo heterociclico, como 2-alfa-antagonistas.
CO5080758A1 (es) DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL
SE8605458D0 (sv) 4-hydroxycoumarin derivatives
ES2140552T3 (es) Derivados indol como inhibidores de la 5-alfa-reductasa-1.
ES2167902T3 (es) Mezclas fungicidas.
DK0963998T3 (da) Azasteroidforbindelse til behandling eller prævention af prostatacancer
ATE61201T1 (de) Fungizide alpha-azolylglykole.
AR247381A1 (es) Compuesto derivado de 2-¡1-(oximino)metil¿-ciclohex-2-en-1-ona sustituido, procedimiento para prepararlo, compuesto intermedio, composicion herbicida y metodo para combatir plantas no deseadas
ES2103675B1 (es) Nuevas piperidinas sustituidas.
ES2036528T3 (es) Procedimiento para la obtencion de derivados aromaticos.
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
DE3272114D1 (de) 4-(4-phenyl-1-piperidinyl)methyl-5-acyl-1,3-dihydro-2h-imidazol-2-ones
ES8105713A1 (es) Un procedimiento para la preparacion de los enatiomeros levogiro y dextrogiro de la 1-ciclopropil-metil-4-(3-metoxi-5h- dibenzo (a,d) ciclohepten-5-iliden) piperidina
GR3007320T3 (OSRAM)

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20000228

FG2A Definitive protection

Ref document number: 994872

Country of ref document: ES